BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
Turnover
16.91%
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+0.6%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$114M
AUM Growth
-$4.18M
(-3.5%)
Cap. Flow
-$1.91M
Cap. Flow
% of AUM
-1.68%
Top 10 Holdings %
Top 10 Hldgs %
30.55%
Holding
133
New
11
Increased
32
Reduced
60
Closed
9
Avg Time Held Equity + Options
1.8
years
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
1.4
years
Avg Time Held Equity only
1.8
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sprott Physical Gold
PHYS
|
+$1.92M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$820K |
| 3 |
BlackRock Core Bond Trust
BHK
|
+$792K |
| 4 |
YHOO
Yahoo Inc
YHOO
|
+$767K |
| 5 |
CLNY
Colony Capital, Inc.
CLNY
|
+$546K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Aerospace
GE
|
+$3.5M |
| 2 |
Apple
AAPL
|
+$2.53M |
| 3 |
Alibaba
BABA
|
+$1.63M |
| 4 |
Realty Income
O
|
+$1.24M |
| 5 |
Microsoft
MSFT
|
+$666K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 19.07% |
| 2 | Real Estate | 17.82% |
| 3 | Healthcare | 11.94% |
| 4 | Technology | 11.86% |
| 5 | Financials | 9.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
GE Aerospace
GE
$317B
| $1.46M | 1.28% |
9,598
-24,755
| -72% | -$3.5M |
2013 Q2
11 quarters
|
|
27
CHS Inc 8% Preferred Stock
CHSCP
$316M
| $1.42M | 1.24% |
45,857
-2,200
| -5% | -$67.8K |
2013 Q2
11 quarters
|
|
28
Sarepta Therapeutics
SRPT
$1.76B
| $1.35M | 1.19% |
69,350
+17,600
| +34% | +$308K |
2013 Q2
11 quarters
|
|
29
DELISTED
Monmouth Real Estate Investment Corp
MNR
| $1.3M | 1.14% |
109,600
-6,500
| -6% | -$70K |
2013 Q2
11 quarters
|
|
30
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$168M
| $1.27M | 1.11% |
83,022
+3,100
| +4% | +$44.4K |
2014 Q3
6 quarters
|
|
31
Healthpeak Properties
DOC
$12.9B
| $1.19M | 1.04% |
40,077
-769
| -2% | -$23.1K |
2013 Q2
11 quarters
|
|
32
Chimera Investment
CIM
$710M
| $1.15M | 1.01% |
28,173
-1,600
| -5% | -$62.2K |
2014 Q1
8 quarters
|
|
33
Merck
MRK
$364B
| $1.11M | 0.98% |
22,055
+629
| +3% | +$30.8K |
2013 Q2
11 quarters
|
|
|
SSW.PRC
34
DELISTED
SEASPAN CORP 9.50% SER C RED PERP PFD SHS (MHL)
SSW.PRC
| $1.1M | 0.97% |
43,645
-1,790
| -4% | -$44.1K |
2013 Q2
11 quarters
|
|
35
KKR & Co
KKR
$76.2B
| $1.06M | 0.93% |
72,301
-5,712
| -7% | -$77.7K |
2014 Q2
7 quarters
|
|
|
36
BlackRock Core Bond Trust
BHK
$590M
| $1.04M | 0.92% |
78,054
+61,200
| +363% | +$792K |
2014 Q4
5 quarters
|
|
37
AT&T
T
$158B
| $1.03M | 0.9% |
34,695
-910
| -3% | -$25.2K |
2015 Q2
3 quarters
|
|
38
Wells Fargo
WFC
$242B
| $999K | 0.88% |
20,650
+4,650
| +29% | +$228K |
2013 Q2
11 quarters
|
|
|
TRIB
39
Trinity Biotech
TRIB
$5.37M
| $974K | 0.85% |
557
-35
| -6% | -$55.7K |
2013 Q2
11 quarters
|
|
40
Goldman Sachs Group Inc Depositary Shares
GS.PRA
$575M
| $954K | 0.84% |
47,969
-2,400
| -5% | -$46.6K |
2013 Q2
11 quarters
|
|
41
Devon Energy
DVN
$54.9B
| $939K | 0.82% |
34,203
+600
| +2% | +$14.6K |
2013 Q2
11 quarters
|
|
42
iShares S&P 100 ETF
OEF
$20.6B
| $842K | 0.74% |
9,215
+2,535
| +38% | +$221K |
2013 Q2
11 quarters
|
|
43
Terex
TEX
$5.96B
| $826K | 0.72% |
33,200
-1,000
| -3% | -$20.9K |
2014 Q3
6 quarters
|
|
|
SSW.PRD
44
DELISTED
Seaspan Corporation 7.95% Series D Cumulative Redeemable Perpetual Preferred Shares
SSW.PRD
| $799K | 0.7% |
32,300
-400
| -1% | -$9.35K |
2013 Q2
11 quarters
|
|
45
DELISTED
Kennedy-Wilson Holdings
KW
| $766K | 0.67% |
35,000
+10,000
| +40% | +$198K |
2013 Q2
11 quarters
|
|
|
46
Teva Pharmaceutical Industries Limited
TEVA
$48B
| $748K | 0.66% |
+13,975
| New | +$820K |
2016 Q1
0 quarters
|
|
47
DELISTED
Vertex Energy, Inc
VTNR
| $678K | 0.59% |
347,769
+107,000
| +44% | +$159K |
2013 Q2
11 quarters
|
|
48
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $664K | 0.58% |
33,000
-4,500
| -12% | -$83.3K |
2013 Q2
11 quarters
|
|
49
Berkshire Hathaway Class A
BRK.A
$1.12T
| $640K | 0.56% |
3
| – | – |
2014 Q1
8 quarters
|
|
50
ConocoPhillips
COP
$171B
| $640K | 0.56% |
15,900
-3,100
| -16% | -$118K |
2013 Q2
11 quarters
|
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, Benchmark Capital Advisors held 133 positions worth $114M, down 3.5% from $118M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Benchmark Capital Advisors's Q1 2016 filing shows 11 new, 32 increased, 60 reduced and 9 closed positions. Its largest new stake was Teva Pharmaceutical Industries Limited: 13,975 shares worth $748K. The largest sale was GE Aerospace, an estimated $3.5M.
By sector, the portfolio is most concentrated in Miscellaneous at 19% of assets, up from 14% a quarter earlier, followed by Real Estate and Healthcare.
- Benchmark Capital Advisors's largest Q1 2016 buy was Teva Pharmaceutical Industries Limited: 13,975 shares worth $748K.
- Benchmark Capital Advisors added most to Sprott Physical Gold in Q1 2016, an estimated $1.92M increase.
- Benchmark Capital Advisors's biggest Q1 2016 reduction was GE Aerospace, cutting an estimated $3.5M.
- Benchmark Capital Advisors fully exited Alibaba in Q1 2016, selling an estimated $1.63M.
- Benchmark Capital Advisors's ten largest holdings make up 31% of its $114M portfolio in Q1 2016.
- Benchmark Capital Advisors opened 11 new positions and closed 9 in Q1 2016.
- Benchmark Capital Advisors's portfolio value fell 3.5% quarter-over-quarter to $114M.
Based on Benchmark Capital Advisors's 13F filing for Q1 2016, filed 10 May 2016.